Patents by Inventor Gayathri Swaminath

Gayathri Swaminath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240327461
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Application
    Filed: June 11, 2024
    Publication date: October 3, 2024
    Applicant: AMGEN INC.
    Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Michael J. FROHN, Brian Alan LANMAN, Anthony B. REED, Leslie P. MIRANDA, John Gordon ALLEN, Alexander J. PICKRELL, Aaron C. SIEGMUND, Lewis D. PENNINGTON, Bryant YANG
  • Patent number: 11807693
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: November 7, 2023
    Assignee: AMGEN INC.
    Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John Gordon Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
  • Patent number: 11191762
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: December 7, 2021
    Assignee: AMGEN INC.
    Inventors: Yinhong Chen, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Philip Dean Ramsden, Ankit Sharma
  • Publication number: 20210261619
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Application
    Filed: January 28, 2021
    Publication date: August 26, 2021
    Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Michael J. FROHN, Brian Alan LANMAN, Anthony B. REED, Leslie P. MIRANDA, John Gordon ALLEN, Alexander J. PICKRELL, Aaron C. SIEGMUND, Lewis D. PENNINGTON, Bryant YANG
  • Patent number: 11046680
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 29, 2021
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Frank Kayser, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Kevin Yang, Wen-Chen Yeh
  • Patent number: 11020395
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 1, 2021
    Assignee: AMGEN INC.
    Inventors: Yinhong Chen, Paul John Dransfield, James S. Harvey, Julie Anne Heath, Jonathan Houze, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Philip Dean Ramsden
  • Patent number: 10941182
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: March 9, 2021
    Assignee: Amgen Inc.
    Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John G. Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
  • Patent number: 10906890
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: February 2, 2021
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Yinhong Chen, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Julie Anne Heath, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Charles Kreiman
  • Patent number: 10736883
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: August 11, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Brown, Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Jonathan Houze, Frank Kayser, Aarif Yusuf Khakoo, David j. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Wen-Chen Yeh
  • Patent number: 10689367
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 23, 2020
    Assignee: AMGEN INC.
    Inventors: Yinhong Chen, Alan C. Cheng, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Vatee Pattaropong, Gayathri Swaminath, Charles Kreiman, David C. Moebius, Ankit Sharma
  • Publication number: 20190300507
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, I or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein.
    Type: Application
    Filed: November 3, 2017
    Publication date: October 3, 2019
    Applicant: AMGEN INC.
    Inventors: Yinhong CHEN, Alan C. CHENG, Mikkel V. DEBENEDETTO, Paul John DRANSFIELD, James S. HARVEY, Jonathan HOUZE, Aarif Yusuf KHAKOO, Su-Jen LAI, Zhihua MA, Vatee PATTAROPONG, Gayathri SWAMINATH, Charles KREIMAN, David C. MOEBIUS, Ankit SHARMA
  • Publication number: 20190290647
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 26, 2019
    Applicant: AMGEN INC.
    Inventors: Yinhong CHEN, Mikkel V. DEBENEDETTO, Paul John DRANSFIELD, James S. HARVEY, Jonathan HOUZE, Aarif Yusuf KHAKOO, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Philip Dean RAMSDEN, Ankit SHARMA
  • Publication number: 20190290648
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 26, 2019
    Applicant: AMGEN INC.
    Inventors: Yinhong CHEN, Paul John DRANSFIELD, James S. HARVEY, Julie Anne HEATH, Jonathan HOUZE, Aarif Yusuf KHAKOO, David J. KOPECKY, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Philip Dean RAMSDEN
  • Publication number: 20190284173
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 19, 2019
    Applicant: AMGEN INC.
    Inventors: Ning CHEN, Yinhong CHEN, Mikkel V. DEBENEDETTO, Paul John DRANSFIELD, James S. HARVEY, Julie Anne HEATH, Jonathan HOUZE, Aarif Yusuf KHAKOO, Su-Jen LAI, Zhihua MA, Nobuko NISHIMURA, Vatee PATTAROPONG, Gayathri SWAMINATH, Wen-Chen YEH, Charles KREIMAN
  • Publication number: 20190275008
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 12, 2019
    Applicant: AMGEN INC.
    Inventors: Matthew BROWN, Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, James S. HARVEY, Julie Anne HEATH, Lars V. HEUMANN, Jonathan HOUZE, Frank KAYSER, Aarif Yusuf KHAKOO, David j. KOPECKY, Su-Jen LAI, Zhihua MA, Julio C. MEDINA, Jeffrey T. MIHALIC, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Malgorzata WANSKA, Wen-Chen YEH
  • Patent number: 10221162
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: March 5, 2019
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser
  • Publication number: 20180319773
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Application
    Filed: July 12, 2018
    Publication date: November 8, 2018
    Applicant: AMGEN INC.
    Inventors: Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, Julie Anne HEATH, Daniel B. HORNE, Jonathan HOUZE, Matthew R. KALLER, Aarif Yusuf KHAKOO, David John KOPECKY, Su-Jen LAI, Zhihua MA, Lawrence R. MCGEE, Julio C. MEDINA, Jeffrey T. MIHALIC, Nobuko NISHIMURA, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Kevin YANG, Wen-Chen YEH, Mikkel V. DEBENEDETTO, Robert P. FARRELL, Simon J. HEDLEY, Ted C. JUDD, Frank KAYSER
  • Patent number: 10058550
    Abstract: Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 28, 2018
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Zice Fu, Julie Anne Heath, Daniel B. Horne, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Zhihua Ma, Jeffrey T. Mihalic, Gayathri Swaminath, Xiaodong Wang, Wen-Chen Yeh
  • Patent number: 9988369
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: June 5, 2018
    Assignee: AMGEN INC.
    Inventors: Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Mikkel V. Debenedetto, Paul John Dransfield, Zice Fu, James S. Harvey, Julie Anne Heath, Simon J. Hedley, Jonathan Houze, Ted C. Judd, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Wen-Chen Yeh
  • Patent number: 9868721
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: January 16, 2018
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Aarif Yusuf Khakoo, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Wen-Chen Yeh, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser